Standardization of an in vitro assay matrix to assess cytotoxicity of organic nanocarriers: a pilot interlaboratory comparison.

Autor: Eder KM; Biomedical Technology Center (BMTZ) of the Medical Faculty, University of Muenster, 48149, Münster, Germany. kai.eder@uni-muenster.de., Marzi A; Biomedical Technology Center (BMTZ) of the Medical Faculty, University of Muenster, 48149, Münster, Germany., Wågbø AM; SINTEF Materials and Chemistry (SINTEF), 7034, Trondheim, Norway., Vermeulen JP; National Institute for Public Health and the Environment (RIVM), 3720 BA, Bilthoven, the Netherlands., de la Fonteyne-Blankestijn LJJ; National Institute for Public Health and the Environment (RIVM), 3720 BA, Bilthoven, the Netherlands., Rösslein M; Swiss Federal Laboratories for Materials Science and Technology (EMPA), CH-9014, St. Gallen, Switzerland., Ossig R; Biomedical Technology Center (BMTZ) of the Medical Faculty, University of Muenster, 48149, Münster, Germany., Klinkenberg G; SINTEF Materials and Chemistry (SINTEF), 7034, Trondheim, Norway., Vandebriel RJ; National Institute for Public Health and the Environment (RIVM), 3720 BA, Bilthoven, the Netherlands., Schnekenburger J; Biomedical Technology Center (BMTZ) of the Medical Faculty, University of Muenster, 48149, Münster, Germany.
Jazyk: angličtina
Zdroj: Drug delivery and translational research [Drug Deliv Transl Res] 2022 Sep; Vol. 12 (9), pp. 2187-2206. Date of Electronic Publication: 2022 Jul 06.
DOI: 10.1007/s13346-022-01203-9
Abstrakt: Nanotechnologies such as nanoparticles are established components of new medical devices and pharmaceuticals. The use and distribution of these materials increases the requirement for standardized evaluation of possible adverse effects, starting with a general cytotoxicity screening. The Horizon 2020 project "Regulatory Science Framework for Nano(bio)material-based Medical Products and Devices (REFINE)" identified in vitro cytotoxicity quantification as a central task and first step for risk assessment and development for medical nanocarriers. We have performed an interlaboratory comparison on a cell-assay matrix including a kinetic lactate dehydrogenase (LDH) release cell death and WST-8 cell viability assay adapted for testing organic nanocarriers in four well-characterized cell lines of different organ origins. Identical experiments were performed by three laboratories, namely the Biomedical Technology Center (BMTZ) of the University of Münster, SINTEF Materials and Chemistry (SINTEF), and the National Institute for Public Health and the Environment (RIVM) of the Netherlands according to new standard operating procedures (SOPs). The experiments confirmed that LipImage™ 815 lipidots ® are non-cytotoxic up to a concentration of 128 µg/mL and poly(alkyl cyanoacrylate) (PACA) nanoparticles for drug delivery of cytostatic agents caused dose-dependent cytotoxic effects on the cell lines starting from 8 µg/mL. PACA nanoparticles loaded with the active pharmaceutical ingredient (API) cabazitaxel showed a less pronounced dose-dependent effect with the lowest concentration of 2 µg/mL causing cytotoxic effects. The mean within laboratory standard deviation was 4.9% for the WST-8 cell viability assay and 4.0% for the LDH release cell death assay, while the between laboratory standard deviation was 7.3% and 7.8% for the two assays, respectively. Here, we demonstrated the suitability and reproducibility of a cytotoxicity matrix consisting of two endpoints performed with four cell lines across three partner laboratories. The experimental procedures described here can facilitate a robust cytotoxicity screening for the development of organic nanomaterials used in medicine.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: